Bank of The West raised its stake in shares of AbbVie Inc (NASDAQ:ABBV) by 5.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 110,715 shares of the company’s stock after buying an additional 5,308 shares during the period. Bank of The West’s holdings in AbbVie were worth $6,559,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of ABBV. Beacon Capital Management boosted its stake in shares of AbbVie by 150.0% in the fourth quarter. Beacon Capital Management now owns 5 shares of the company’s stock valued at $0 after buying an additional 3 shares during the period. Community Bank & Trust of Waco, Texas purchased a new stake in shares of AbbVie during the fourth quarter valued at $1,819,000. Vicus Capital purchased a new stake in shares of AbbVie during the fourth quarter valued at $258,000. Central Bank & Trust Company boosted its stake in shares of AbbVie by 1.2% in the fourth quarter. Central Bank & Trust Company now owns 4,596 shares of the company’s stock valued at $272,000 after buying an additional 54 shares during the period. Finally, NewSquare Capital LLC boosted its stake in shares of AbbVie by 15.0% in the fourth quarter. NewSquare Capital LLC now owns 5,125 shares of the company’s stock valued at $304,000 after buying an additional 667 shares during the period.

AbbVie Inc (NASDAQ:ABBV) opened at 57.11 on Thursday. The company has a 50-day moving average of $56.84 and a 200-day moving average of $60.39. AbbVie Inc has a 52-week low of $45.45 and a 52-week high of $71.60. The stock has a market capitalization of $93.36 billion and a price-to-earnings ratio of 33.13.

AbbVie (NASDAQ:ABBV) last released its quarterly earnings results on Friday, October 30th. The company reported $1.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.05. The company earned $4.94 billion during the quarter, compared to analysts’ expectations of $5.90 billion. During the same quarter in the prior year, the company earned $0.89 EPS. The firm’s revenue was up 18.4% compared to the same quarter last year. Equities research analysts expect that AbbVie Inc will post $4.29 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.99%. The ex-dividend date is Wednesday, January 13th. This is a boost from AbbVie’s previous quarterly dividend of $0.51.

Several analysts recently weighed in on the stock. Vetr cut shares of AbbVie from a “hold” rating to a “sell” rating and set a $61.73 target price on the stock. in a report on Monday, November 9th. Argus reaffirmed a “buy” rating and issued a $63.23 target price (down previously from $85.00) on shares of AbbVie in a report on Tuesday, November 10th. TheStreet raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Friday, November 6th. Credit Suisse raised their target price on shares of AbbVie from $77.00 to $78.00 and gave the company an “outperform” rating in a report on Monday, November 2nd. Finally, Morgan Stanley raised shares of AbbVie from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $62.00 to $73.00 in a report on Monday, November 2nd. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. AbbVie has an average rating of “Buy” and a consensus price target of $71.22.

AbbVie Inc. (NASDAQ:ABBV) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

12 Month Chart for NASDAQ:ABBV

Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.